Skip to content
    ARCH Venture Partners logo

    ARCH Venture Partners

    Chicago, Illinois, United StatesFounded 1986
    www.archventure.comLinkedIn
    Biotech & Life SciencesHealthcare

    ARCH Venture Partners is an early-stage venture capital firm that focuses on building and funding companies based on breakthrough science, primarily in life sciences, biotechnology, and related deep-tech domains. Their strategy involves partnering with leading scientists and research institutions to commercialize disruptive innovations.

    Find people at ARCH Venture Partners on Goldilocks AI

    Portfolio

    26

    Fund Size

    $10.6B

    Top Stage

    Series B

    Last 12 Mo

    6

    Team

    CB

    Clinton Bybee

    Co-founder & Managing Director, Emeritus

    KC

    Keith Crandell

    Co-founder & Managing Director

    RN

    Robert Nelson

    Co-Founder and Managing Director

    SG

    Steven Gillis

    Managing Director

    AN

    Ari Nowacek, M.D, Ph.D.

    Partner

    BC

    Brian Cuneo

    Senior Partner

    GS

    George Scangos, Ph.D.

    Venture Partner

    IC

    Inca Coman, Ph.D.

    Venture Partner

    JJ

    Joseph Jeong, Ph.D.

    Venture Partner

    LB

    Luciana Borio, M.D.

    Venture Partner

    MC

    Mary Chamberlain-Tharp, Ph.D.

    Venture Partner

    MY

    Mayu Yoshikawa, Ph.D.

    Venture Partner

    Stage Distribution

    Portfolio

    26 investments
    CompanyRoundAmountDate
    SciNeuro PharmaceuticalsSeries C$53MDec 2025
    Paradigm HealthSeries B$78MDec 2025
    Aspen NeuroscienceSeries C$115MNov 2025
    Lifordi ImmunotherapeuticsUnknown—Nov 2025
    Gate BioscienceSeries B$65MNov 2025
    Elephas Biosciences CorporationSeries B$40MNov 2025
    Human Immunology Biosciences (HI-Bio)Series B$95MJan 2024
    Gate BioscienceSeries A$60MNov 2023
    Magnet BiomedicineSeries A$50MSep 2023
    Rapport TherapeuticsSeries B$150MAug 2023
    Protillion BiosciencesSeries A$18MDec 2022
    SynchronSeries C$75MDec 2022
    RipplSeed$32MSep 2022
    Happy HealthSeries A$60MAug 2022
    Homeward HealthSeries B$50MAug 2022
    Aspen NeuroscienceSeries B$147.5MMay 2022
    Pheast TherapeuticsSeries A$76MApr 2022
    Arbor Biotechnologies IncSeries B$215MNov 2021
    Prime MedicineSeries B$200MJul 2021
    Remix TherapeuticsSeries A$81MDec 2020
    Bit BioSeries B$41.5MJun 2020
    Aspen NeuroscienceSeries A$70MApr 2020
    Aspen NeuroscienceSeed$6.5MDec 2019
    LunaPBCSeed$4.6MMay 2019
    Brii BioSciencesSeries D$260MMay 2018
    Page 1 of 2

    Top Co-Investors

    GV (Google Ventures)6 shared
    OrbiMed4 shared
    Alexandria Venture Investments4 shared
    F-Prime Capital4 shared
    General Catalyst3 shared
    Section 323 shared
    Illumina Ventures3 shared
    Frazier Life Sciences2 shared
    Lifeforce Capital2 shared
    Cormorant Asset Management2 shared
    Atlas Venture2 shared
    Foresite Capital2 shared
    Tao Capital Partners2 shared
    Versant Ventures2 shared
    Human Ventures1 shared
    S321 shared
    Balyasny Asset Management1 shared
    Sofinnova Partners1 shared
    Fidelity Management & Research Company1 shared
    Goldman Sachs1 shared

    Last updated: 1 March 2026